Spots Global Cancer Trial Database for orr
Every month we try and update this database with for orr cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome | NCT01053806 | Myelodysplastic... | 5-Azacytidine a... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT03376958 | Relapsed and Re... Diffuse Large B... | Apatinib | 14 Years - 70 Years | Zhengzhou University | |
| Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | NCT03422029 | Neuroendocrine ... | 177Lu-Dotatate ... | 18 Years - | Peking University | |
| Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma | NCT03168607 | Neuroendocrine ... | FOLFIRI Protoco... | 18 Years - | Peking University | |
| Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | NCT04083066 | Primary Central... | rituximab in co... | 14 Years - 75 Years | Zhengzhou University | |
| Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor | NCT03279601 | Neuroendocrine ... | Capecitabine, D... Capecitabine, T... | 18 Years - | Peking University | |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT03376958 | Relapsed and Re... Diffuse Large B... | Apatinib | 14 Years - 70 Years | Zhengzhou University | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | NCT05670106 | Metastatic Cast... | [177Lu]Lu-PSMA-... Best supportive... 68Ga-PSMA-11 | 18 Years - | Novartis | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | NCT05670106 | Metastatic Cast... | [177Lu]Lu-PSMA-... Best supportive... 68Ga-PSMA-11 | 18 Years - | Novartis | |
| Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma | NCT03168594 | Neuroendocrine ... | irinotecan cisp... Etoposide cispl... | 18 Years - | Peking University | |
| Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome | NCT01053806 | Myelodysplastic... | 5-Azacytidine a... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | NCT01811277 | Biliary Tract C... Periampullary A... Pancreatic Canc... | SOX sequential ... | 18 Years - 75 Years | Peking University | |
| Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | NCT03422029 | Neuroendocrine ... | 177Lu-Dotatate ... | 18 Years - | Peking University | |
| Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL | NCT03707847 | ALK-Positive An... | Crizotinib Etoposide Capsu... Auto-HSCT | 14 Years - 65 Years | Zhengzhou University | |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | NCT04831658 | Primary Central... | the dose-escala... | 18 Years - 69 Years | Zhengzhou University | |
| A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | NCT02586857 | Glioblastoma Mu... | ACP-196 | - | Acerta Pharma BV | |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | NCT04831658 | Primary Central... | the dose-escala... | 18 Years - 69 Years | Zhengzhou University | |
| Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor | NCT03279601 | Neuroendocrine ... | Capecitabine, D... Capecitabine, T... | 18 Years - | Peking University | |
| A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma | NCT03579082 | Diffuse Large B... | Decitabine | 14 Years - 65 Years | Zhengzhou University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
